Company Information

Eden Research plc announced preliminary results for the 15 months ended 31 March 2026, reporting revenue of £4.9 million and an operating loss of £2.9 million. The company's cash position stood at £1.5 million at period-end, following a gross fundraise of £10.8 million, with £7.6 million received post period-end. During this period, Eden Research secured product approvals for Mevalone in California and France, Ecovelex in Italy for the 2026 growing season, and Novellus+ in Chile, also entering new distribution agreements.

RNS Metadata